Kyowa Kirin Co., Ltd. provided consolidated earnings guidance for the full year ending December 31, 2024. For the full year, the company expects net revenue of JPY 473,000 million, core operating profit of JPY 85,000 million and profit of JPY 63,000 million or JPY 119.07 per basic share.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,668 JPY | 0.00% | +1.43% | +12.55% |
May. 02 | BridgeBio Pharma Shares Decline After Q1 Financial Results | MT |
Apr. 08 | U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.55% | 9.3B | |
+5.48% | 71.19B | |
-13.75% | 5.01B | |
+42.38% | 4.47B | |
+4.51% | 3.96B | |
+21.10% | 2.44B | |
-19.05% | 2.41B | |
-28.72% | 2.23B | |
+11.13% | 2.02B | |
+6.53% | 1.69B |
- Stock Market
- Equities
- 4151 Stock
- News Kyowa Kirin Co. Ltd.
- Kyowa Kirin Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024